You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Chimeric Antigen Receptor T Cells

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

19 and 22+ B Cell Hematologic Tumors Trial in Wuhan (Autologous CD19/CD22 Chimeric Antigen Receptor T-cells)

Recruiting
  • 19 and 22+ B Cell Hematologic Tumors
  • 19 and 20+ B Cell Hematologic Tumors
  • Autologous CD19/CD22/CD20 Chimeric Antigen Receptor T-cells
  • Wuhan, Hubei, China
    Tongji Hospital
Jan 11, 2023

Refractory Multiple Myeloma, Relapsed Multiple Myeloma Trial in San Francisco (Manufactured Anti-BCMA CAR-T cells, Fludarabine,

Recruiting
  • Refractory Multiple Myeloma
  • Relapsed Multiple Myeloma
  • Manufactured Anti-BCMA CAR-T cells
  • +2 more
  • San Francisco, California
    University of California, San Francisco
Jan 6, 2023

Small Cell Lung Cancer Extensive Stage, Large Cell Neuroendocrine Carcinoma of the Lung Trial (LB2102)

Not yet recruiting
  • Small Cell Lung Cancer Extensive Stage
  • Large Cell Neuroendocrine Carcinoma of the Lung
  • LB2102
  • (no location specified)
Jan 10, 2023

Chronic Lymphocytic Leukemia, B-Cell Chronic Lymphocytic Leukemia, Lymphoma, B-Cell Trial run by the National Cancer Institute

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • +2 more
  • Anti-CD19 and anti-CD20 bicistronic CAR T- cells
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Apr 10, 2023

SLE (Systemic Lupus) Trial in Bangkok (CAR T-cell therapy)

Not yet recruiting
  • SLE (Systemic Lupus)
  • CAR T-cell therapy
  • Bangkok, Please Select, Thailand
    King Chulalongkorn Memorial Hospital
Nov 23, 2023

Colorectal Cancer, Esophagus Cancer, Gastric Cancer Trial in Hangzhou (CEA-targeted CAR-T cells)

Recruiting
  • Colorectal Cancer
  • +6 more
  • CEA-targeted CAR-T cells
  • Hangzhou, Zhejiang, China
  • +1 more
Sep 18, 2023

Gastric Cancer, Gastroesophageal-junction Cancer, Esophageal Cancer Trial (LB1908)

Not yet recruiting
  • Gastric Cancer
  • +3 more
  • LB1908
  • (no location specified)
Sep 9, 2022

Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia Trial in Beijing

Recruiting
  • Acute Lymphoblastic Leukemia
  • +2 more
  • Autologous humanized anti-CD22 chimeric antigen receptor T cells
  • Beijing, Beijing, China
    Beijing Boren Hospital
Aug 12, 2022

Brain and Nervous System Trial in Palo Alto (B7-H3CART)

Recruiting
  • Brain and Nervous System
  • Palo Alto, California
    Stanford Cancer Institute
Jul 22, 2022

Lymphoid Leukemia Trial in Palo Alto (Allogeneic donor-derived T-cells transduced with bivalent lentiviral vector

Not yet recruiting
  • Lymphoid Leukemia
  • Allogeneic donor-derived T-cells transduced with bivalent lentiviral vector (CD19/CD22-BBz) chimeric antigen receptor (CAR)
  • Treg CD34+ HSPC (Orca-T)
  • Palo Alto, California
    Stanford Cancer Center
Aug 17, 2022

Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma Trial in Suzhou (Chimeric Antigen Receptor T Cells (CAR-T) Targeting Igß

Recruiting
  • Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
  • Chimeric Antigen Receptor T Cells (CAR-T) Targeting Igβ Targets
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Apr 3, 2022

Solid Tumor, Hematological Malignancy Trial in Beijing (Metoprolol, metoprolol, infliximab, etanercept, tocilizumab and/or other

Recruiting
  • Solid Tumor
  • Hematological Malignancy
  • Metoprolol
  • metoprolol, infliximab, etanercept, tocilizumab and/or other agents
  • Beijing, Beijing, China
    Biotherapeutic Department of Chinese PLA General Hospital
Apr 8, 2022

Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia Trial in Cleveland (Fully human anti CD19 CAR-T

Recruiting
  • Non Hodgkin Lymphoma
  • +2 more
  • Fully human anti CD19 CAR-T Cell Dose
  • +2 more
  • Cleveland, Ohio
    University Hospitals Cleveland Medical Center, Case Comprehensiv
Oct 4, 2022

Acute Lymphocytic Leukemia Trial in Tianjin (CD19-targeted Chimeric Antigen Receptor (CAR) T Cells)

Recruiting
  • Acute Lymphocytic Leukemia
  • CD19-targeted Chimeric Antigen Receptor (CAR) T Cells
  • Tianjin, Tianjin, China
    Hematology Hospital, Chinese Academy of Medical Sciences
Feb 5, 2023

Myasthenia Gravis Trial in Hangzhou (CD19 CAR-T cells injection)

Recruiting
  • Myasthenia Gravis
  • CD19 CAR-T cells injection
  • Hangzhou, Zhejiang, China
    The first affiliated hospital of medical college of zhejiang uni
Apr 12, 2023

Neuromyelitis Optica Trial in Hangzhou (CD19 CAR-T cells injection)

Recruiting
  • Neuromyelitis Optica
  • CD19 CAR-T cells injection
  • Hangzhou, Zhejiang, China
    The first affiliated hospital of medical college of zhejiang uni
Apr 12, 2023

Hepatocellular Carcinoma Trial in China (CAR-GPC3 T Cells)

Completed
  • Hepatocellular Carcinoma
  • CAR-GPC3 T Cells
  • Guangzhou, Guangdong, China
  • +5 more
Feb 8, 2022

B Cell Acute Lymphoblastic Leukemia (B-ALL), B Lineage Lymphoblastic Lymphoma Trial (Autologous Humanized CD19-Directed Chimeric

Not yet recruiting
  • B Cell Acute Lymphoblastic Leukemia (B-ALL)
  • B Lineage Lymphoblastic Lymphoma
  • Autologous Humanized CD19-Directed Chimeric Antigen Receptor T-Cells (huCART19)
  • (no location specified)
Jul 27, 2022

Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia Refractory, B-cell Lymphoma Recurrent Trial in São Paulo

Not yet recruiting
  • Acute Lymphoblastic Leukemia, in Relapse
  • +5 more
  • São Paulo, Brazil
    Hospital Israelita Albert Einstein
Jan 20, 2023

Platinum-Resistant Ovarian Carcinoma Trial in Duarte (Chimeric Antigen Receptor T-cells, Cyclophosphamide, Fludarabine)

Recruiting
  • Platinum-Resistant Ovarian Carcinoma
  • Chimeric Antigen Receptor T-cells
  • +2 more
  • Duarte, California
    City of Hope Medical Center
Jul 21, 2022

Non-Hodgkin Lymphoma Trial in Saint Louis, Cleveland (Cyclophosphamide, Fludarabine, CAR-T Cells)

Active, not recruiting
  • Non-Hodgkin Lymphoma
  • Saint Louis, Missouri
  • +1 more
Mar 10, 2022

Neuroblastoma Trial (GD2 CAR T cells)

Not yet recruiting
  • Neuroblastoma
  • GD2 CAR T cells
  • (no location specified)
Aug 5, 2023

Advanced Sarcoma Trial (NKG2D-CAR memory T cell)

Not yet recruiting
  • Advanced Sarcoma
  • NKG2D-CAR memory T cell
  • (no location specified)
Oct 17, 2023

Advanced Pancreatic Carcinoma Trial in Shenzhen (CD276 CAR-T cells)

Recruiting
  • Advanced Pancreatic Carcinoma
  • CD276 CAR-T cells
  • Shenzhen, Guangdong, China
    Li Yu
Dec 2, 2021

Relapsed and/or Refractory Multiple Myeloma Trial in Köln (BMS-986453, Fludarabine, Cyclophosphamide)

Not yet recruiting
  • Relapsed and/or Refractory Multiple Myeloma
  • Köln, Germany
    Local Institution - 0017
Dec 4, 2023